Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Pharma & Biotech

ITI-9001 enters Phase 1 as Immunomic Therapeutics tests disease-modifying allergy vaccine

See how ITI-9001 could reshape Japanese cedar allergy treatment and what its Phase 1 trial must prove on safety, efficacy and durability.

Read More
Medical Devices & Diagnostics

Visby Medical’s FDA-cleared at-home PCR could reshape flu and COVID-19 testing

Discover how Visby Medical’s FDA-cleared at-home PCR could reshape flu and COVID-19 testing, treatment access, and diagnostics competition.

Read More
Medical Devices & Diagnostics

Is Vilo Signal OS truly different from Oura Advisor and WHOOP’s proactive AI?

Discover how Vilo Signal OS plans to turn smart ring data into proactive health guidance, and why validation, privacy and trust will decide its future.

Read More
Pharma & Biotech

Evidation GLP-1 study reveals major growth runway but exposes widening access gaps

Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.

Read More
Representative image: Nona Biosciences and Lonza are developing a single-domain antibody platform designed to improve blood-brain barrier crossing and support next-generation central nervous system drug delivery.
Pharma & Biotech

Why the Nona Biosciences and Lonza alliance matters for brain-penetrant biologics

Nona Biosciences and Lonza are building a single-domain antibody platform to cross the blood-brain barrier. Explore the clinical and licensing stakes.

Read More
Ribo and Madrigal have advanced their first siRNA drug candidate for MASH into IND-enabling studies, highlighting the growing role of gene-silencing therapies in liver disease treatment. Representative image.
Pharma & Biotech

Madrigal expands MASH strategy as first Ribo siRNA candidate enters IND preparation

Discover why Ribo and Madrigal’s first nominated siRNA candidate could reshape genetically targeted and combination treatment strategies in MASH.

Read More
Abbisko Therapeutics and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated non-small cell lung cancer, putting safety, pneumonitis risk and treatment durability under close scrutiny. Representative image.
Pharma & Biotech

AstraZeneca adds Abbisko’s lumipodlin to expanding Tagrisso combination strategy

Discover why Abbisko and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated lung cancer.

Read More
Representative image: AI-driven pharmaceutical research combining advanced molecular modelling, laboratory automation and drug discovery workflows, reflecting the strategic collaboration between Insilico Medicine and Takeda Pharmaceutical Company.
Pharma & Biotech

Insilico Medicine secures Takeda collaboration to advance AI-designed drug candidates

Discover how Takeda’s $600 million Insilico Medicine collaboration could reshape AI drug discovery, candidate design and clinical translation.

Read More
Otsuka’s VOYXACT Phase 3 VISIONARY results showed sustained kidney function benefits in adults with IgA nephropathy, strengthening the case for long-term disease modification and full regulatory approval. Representative image.
Pharma & Biotech

Otsuka reports VOYXACT preserved kidney function for two years in Phase 3 trial

Otsuka’s two-year VOYXACT data could reshape IgA nephropathy care. See what the eGFR results mean for FDA approval and clinical adoption.

Read More
Pharma & Biotech

DEA targets enhanced 7-OH products with proposed Schedule I controls

Read how DEA’s proposed Schedule I controls for enhanced 7-OH could reshape kratom products, enforcement and research in the United States.

Read More